Convatec strengthens Leadership Team to support growth

• Newly created role of Chief Commercial Officer to further enhance commercial execution
• New President & Chief Operating Officer for largest Business Unit Advanced Wound Care
  
• New leader for ConvaNiox^TM to scale breakthrough technology 

2 September 2025, London, UK – Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, today announces strengthening of its Executive Leadership Team (CELT) and a key senior leadership appointment.

David Shepherd, currently President & Chief Operating Officer, Advanced Wound Care, has been appointed Chief Commercial Officer for the Group. Reflecting Convatec’s strong track record and growth ambition, the newly created role will support Jonny Mason, Convatec’s Interim Chief Executive Officer and its five Business Unit Presidents. Working across the business, David will further sharpen our focus on commercial execution excellence, customer centricity and sharing best practice, including existing business and new product launches. He will also have responsibility for Convatec’s Centres of Excellence for Global Marketing & Sales and Strategic Pricing.

David joined Convatec in November 2018. He was previously at Johnson and Johnson (J&J) for 26 years. In his later roles at J&J, David spent 7 years as President of various businesses, including US President for Cardiovascular and Specialty Services and Global President for Biosense Webster. At Convatec, David has led the transformation of our wound care business, which now boasts the industry’s most ambitious wound care new product pipeline, focused on helping improve care for millions of people around the world.

David commented: “Convatec is a brilliant business, with wonderful colleagues, dedicated to making our promise of forever caring a reality for customers around the world. I’m looking forward to taking on this new role at an important moment for the company as we accelerate our efforts to bring to life the richest innovation pipeline in the company’s history.”

Tanja Dormels has been appointed as President & Chief Operating Officer for Advanced Wound Care.

Tanja joined Convatec in January 2019 and has spent over 25 years in leadership roles across the medical technology, biopharma and pharmaceutical industry. Prior to Convatec, she has held roles with companies including Sandoz and Novartis, and previously served on the Board of HEXAL AG, a German pharmaceutical company, part of the Sandoz Group.

At Convatec, Tanja led Advanced Wound Care in Europe until 2024, when she was appointed to lead the newly formed team which brought to market our breakthrough nitric oxide wound dressing technology, ConvaNiox^TM in 2025. The appointment further demonstrates Convatec’s commitment to talent development and career progression.

Tanja commented: “I’m really proud to be taking on leadership of Convatec’s Advanced Wound Care business. Millions of people around the world already count on our products, and working with our talented AWC colleagues, I am excited to lead our efforts to ensure even more patients and healthcare professionals can benefit from them in the years ahead.”

Changes are effective 1 October. Click here to see the full Convatec Executive Leadership Team.

Convatec is delighted to welcome Emmanuèle Claeys as General Manager for ConvaNiox^TM, effective 1 September as the business starts to launch its breakthrough technology platform. Emma brings over 20 years of international experience across both Biopharma and consumer goods. She joins Convatec following her most recent role at Kyowa Kirin International, where she was General Manager, Northern Cluster. Prior to this, she spent 13 years at Eli Lilly & Company in range of commercial roles in Belgium, the United Kingdom and the United States.

Emmanuèle commented: “I am delighted to join Convatec, a company deeply committed to its vision of pioneering trusted medical solutions to improve the lives we touch. ConvaNioxTM is a breakthrough platform with significant untapped potential. I’m excited to lead the talented team working on unlocking that potential to ensure many more people can benefit.”

Contacts
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com